





New Developments in NMR

Edited by Leoncio Garrido and Nicolau Beckmann

# New Applications of NMR in Drug Discovery and Development



RSC Publishing

# ***New Applications of NMR in Drug Discovery and Development***

Edited by

**Leoncio Garrido**

*Consejo Superior de Investigaciones Científicas, Spain*

*Email: lgarrido@cetef.csic.es*

**Nicolau Beckmann**

*Novartis Institutes for BioMedical Research, Switzerland*

*Email: nicolau.beckmann@novartis.com*



RSC Publishing

New Developments in NMR No. 2

ISBN: 978-1-84973-444-8

ISSN: 2044-253X

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2013

*All rights reserved*

*Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.*

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,  
Thomas Graham House, Science Park, Milton Road,  
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our website at [www.rsc.org](http://www.rsc.org)

# New Applications of NMR in Drug Discovery and Development

## New Developments in NMR

### *Editor-in-Chief:*

Professor William S. Price, *University of Western Sydney, Australia*

### *Series Editors:*

Professor Bruce Balcom, *University of New Brunswick, Canada*

Professor István Fűrő, *Industrial NMR Centre at KTH, Sweden*

Professor Masatsune Kainosho, *Nagoya University, Japan*

Professor Maili Liu, *Chinese Academy of Sciences, Wuhan, China*

### *Titles in the Series:*

- 1: Contemporary Computer-Assisted Approaches to Molecular Structure Elucidation
- 2: New Applications of NMR in Drug Discovery and Development

### *How to obtain future titles on publication:*

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

### *For further information please contact:*

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247

Email: [booksales@rsc.org](mailto:booksales@rsc.org)

Visit our website at [www.rsc.org/books](http://www.rsc.org/books)

# Preface

Nuclear Magnetic Resonance (NMR) is a most informative tool for gaining insight into the inner workings of nature and is useful in many fields of applied science. The gained knowledge allows us to develop advanced medical methods of treating diseases and to develop preventive procedures. Often NMR represents even the ultimate tool of insight in drug discovery and development, for example. The information gained by NMR is in the correct form expected by a medical scientist and it can be applied directly for discovering new potential drugs and for working out prescriptions of their optimum application to treat diseases.

The comprehension of biomedical effects, induced by drugs, requires a molecular view. Molecules are interacting and are leading to beneficial results or to harmful side effects. In this sense, pharmaceutical science is part of applied chemistry where molecules are the objects of central interest. Without a molecular view, it is difficult to understand the functioning of drugs. There is a fortuitous match between the demands of pharmaceutical practice and the outstanding features of NMR as an investigative tool. The results of NMR experiments are also best understood in terms of molecular interactions. This is one of the reasons for the unique importance of NMR in biomedicine. Comprehension is often a question of using the correct language and the proper terms that can be understood and applied directly in the relevant biomedical context.

The match between measurement results and the biomedical needs is implemented rather perfectly in the various chapters of this comprehensive treatise. The *Part I. Small Molecules, Proteins, Cellular Systems*, reflects the fact that many of the most potent drugs are small molecules. Indeed, nature takes advantage of small molecules as agents and transporters with their multivariate functions that adapt well to the needs of the biomedical organism. Small molecules are easier to tailor-make to match the requirements, their

---

New Developments in NMR No. 2

New Applications of NMR in Drug Discovery and Development

Edited by Leoncio Garrido and Nicolau Beckmann

© The Royal Society of Chemistry 2013

Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)

synthesis is manageable in an industrial environment and they are easier to comprehend. Small proteins are the first choices of nature as well as of the drug designer who has to take into account the specific properties of the cellular environment where the drugs must exert their action.

In many, if not in most circumstances, an extreme reductionist approach of analytical science is inappropriate. Physiological action involves the entire biological organism and can not be understood solely in terms of its parts. This view is reflected in *Part II. The Whole Organism in Vivo*, where it is attempted to balance an analytical approach with a holistic view of the entire organism. Again, NMR is astonishingly adaptive to the various degrees of focusing. NMR technology acts like a universal microscope that can be adapted to macroscopic objects, such as a human heart or a brain, or focused onto nano-scale objects, such as cells and tissues, or used to explore truly molecular processes, like the interaction of proteins and nucleic acids. Various tools of magnetic resonance allow the focusing onto the features of actual interest. Many of them are described in this book. They lead to the remarkable adaptability of NMR to the actual practical situation.

In *Part III. Translational drug discovery: From Biological Models to the Clinics*, the possibilities of NMR and MRI are discussed in the context of a number of relevant clinical applications of magnetic resonance techniques, from tissue engineering, to the exploration of psychiatric disorder, to neurodegenerative diseases, to respiratory diseases, to cardiac MR, and finally to MR applications in cancer.

This volume convincingly demonstrates the enormous breadth of MRI applications in biomedicine. The utility of modern NMR and MRI becomes even more impressive when one realizes that biomedicine is only one of the potential fields of fruitful application of magnetic resonance technology. Other fields are developing equally rapidly today, including magnetic resonance studies of battery materials, NMR in the context of nanotechnology, and materials research in general, to mention just a few. One of the most important fields is and will remain the study of protein and nucleic acid interactions for biomedical understanding and for drug design.

In summary, the volume "New Applications of NMR in Drug Discovery and Development" represents an important addition to the bookshelf of anybody seriously interested in drug discovery and development. It will remain a reliable source of information in this important field for many years to come. I would like to congratulate and thank Nicolau Beckmann and Leoncio Garrido for their efforts towards such a comprehensive survey on this field of remarkable current activity.

Richard R. Ernst  
Laboratorium für Physikalische Chemie  
ETH Zürich, Switzerland

# Contents

<b>Introduction</b>	<b>1</b>
<i>Leoncio Garrido and Nicolau Beckmann</i>	
 <b>Part I Small Molecules, Proteins, Cellular Systems</b>	
<b>Chapter 1 New Applications of High-Resolution NMR in Drug Discovery and Development</b>	<b>7</b>
<i>María del Carmen Fernández-Alonso, Manuel Alvaro Berbis, Ángeles Canales, Ana Ardá, Francisco Javier Cañada and Jesús Jiménez-Barbero</i>	
1.1 Introduction and Historical Perspective	7
1.2 NMR Techniques for Molecular Recognition	
Studies Based on Monitoring Ligand Resonances	9
1.2.1 Fundamentals	9
1.2.2 Basic Hardware Description	13
1.2.3 The Basic Experiments: STD, WaterLOGSY and Their Variants	13
1.2.4 Further Developments	18
1.2.5 Employing Other Nuclei ( $^{19}\text{F}$ )	23
1.3 NMR Techniques and Applications Based on Monitoring the Receptor Resonances	25
1.3.1 Fundamentals: A Brief Overview of Biomolecular Structure Elucidation by NMR	25
1.3.2 HSQC and Their Variants. SAR by NMR	26
1.4 Mixed Protocols	27
1.4.1 Screening. Fragment-Based Drug Design	27

---

New Developments in NMR No. 2

New Applications of NMR in Drug Discovery and Development

Edited by Leoncio Garrido and Nicolau Beckmann

© The Royal Society of Chemistry 2013

Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)



1.5	Frontiers	31
1.5.1	Towards Larger and Larger Systems: Labeling Strategies and Instrumentation	31
1.5.2	Membrane Proteins	34
1.6	Conclusions	36
	References	36
<b>Chapter 2</b>	<b>Solid-State NMR in Drug Discovery and Development</b>	<b>43</b>
	<i>Frederick G. Vogt</i>	
2.1	Introduction	43
2.2	Background	44
2.2.1	Theoretical Background	44
2.2.2	Instrumentation	52
2.2.3	Experimental Methods	54
2.2.4	Computational Methods	64
2.2.5	Special Processing Methods	68
2.3	Applications to Drug Discovery	68
2.3.1	Labeled Biomolecules	69
2.3.2	Oriented Biomolecules	72
2.3.3	Metal Sites in Proteins and Other Biological Macromolecules	73
2.3.4	Drug–Receptor Interactions	75
2.3.5	Protein–Protein Interactions and Interactions Between Biomolecules	76
2.3.6	Future Directions	78
2.4	Applications to Drug Development	78
2.4.1	Polymorphism	79
2.4.2	Hydrates, Solvates, Salts and Cocrystals	84
2.4.3	Disordered Forms	85
2.4.4	Amorphous Drugs	85
2.4.5	Excipients	87
2.4.6	Formulations and Dispersions of Drugs	88
2.4.7	Crystal Structure Determination	89
2.4.8	Future Directions	90
2.5	Conclusions	90
	References	91
<b>Chapter 3</b>	<b>High-Resolution NMR-Based Metabolic Profiling in Drug Discovery and Development</b>	<b>101</b>
	<i>Nigel J. Waters</i>	
3.1	Background to Metabolic Profiling by NMR Spectroscopy	101
3.2	Advancements in NMR Spectroscopy	104

3.3	Applications in Drug Discovery and Development	110
3.3.1	Understanding of Disease Etiology in Pre-Clinical Models	110
3.3.2	Toxicology and Safety Assessment	118
3.3.3	Drug Metabolism and Pharmacokinetics	121
3.3.4	Clinical Applications	123
3.4	Summary and Future Directions	126
	Acknowledgements	127
	References	127
<b>Chapter 4</b>	<b>In-Cell NMR Spectroscopy to Study Protein–Drug Interactions</b>	<b>134</b>
	<i>Jacqueline D. Washington, David S. Burz and Alexander Shekhtman</i>	
4.1	Introduction	134
4.2	In-Cell NMR Spectroscopy	135
4.2.1	Cell Types	136
4.2.2	Target Labeling	138
4.2.3	In-Cell Delivery of Protein Target Molecules	139
4.3	Methods and Applications	144
4.3.1	STRUCTURAL INTERACTIONS NMR (STINT-NMR)	144
4.3.2	Protein Maturation	146
4.3.3	Metabolic Processing of Proteins	148
4.3.4	Regulation of Post-Translational Modifications (In-Cell Biochemistry)	149
4.3.5	De Novo Structure Determination	152
4.4	Drug Screening	153
4.4.1	In-Cell Delivery of Drug Molecules	153
4.4.2	Screening of Small Molecule Interactor Library NMR (SMILI-NMR)	155
4.5	Conclusions	157
	References	158

## Part II The Whole Organism *In Vivo*

### Anatomy, Function, Metabolism and Cellular/Molecular Imaging

<b>Chapter 5</b>	<b>Increased Sensitivity Using Cryogenic Radiofrequency Coils: Application to <i>In Vivo</i> Phenotyping of Mice</b>	<b>165</b>
	<i>J. Klohs, A. Seuwen, A. Schröter, D. Marek and M. Rudin</i>	
5.1	Introduction	165
5.1.1	Mouse Models in Biomedical Research	165
5.1.2	Challenges in MRI Phenotyping of Mice	166

5.2	Cryogenic RF Coils as a Tool in Small Animal MRI	167
5.2.1	Improving Signal-to-Noise Ratio by Lowering the Coil Temperature: Theoretical Background	167
5.2.2	Comparison of Signal-to-Noise Ratio Obtained with Room Temperature and Cryogenic RF Coils	171
5.3	Cryogenic RF Coils for Mouse Phenotyping	172
5.3.1	Application of Cryogenic RF Coils for High-Resolution MR Imaging	172
5.3.2	The Use of Cryogenic RF Coils for Functional MRI of the Mouse Brain	174
5.3.3	Metabolic Phenotyping Using MRS and Chemical Shift Imaging	177
5.3.4	Advantages and Limitations of Cryogenic RF Coils for Mouse Phenotyping	178
	References	181

## **Chapter 6 Recent Developments of Contrast Agents, CEST and Low Fields** **184**

*S. Aime and D. L. Longo*

6.1	Introduction	184
6.2	Gd(III)-Based Contrast Agents	185
6.2.1	Determinants of the Relaxivity of Gd(III) Complexes	185
6.2.2	Gd(III)-Based Contrast Agents with $q > 1$	188
6.2.3	Nanosized Carriers	189
6.3	CEST (Chemical Exchange Saturation Transfer) Agents	190
6.3.1	Iopamidol and Iopromide as DIACEST Agents	191
6.3.2	Yb-HPDO3A as PARACEST Agent	194
6.3.3	Multiplexing Detection of Cells Labeled with PARACEST Agents	194
6.4	Contrast Agents & Low Fields MRI Scanners	196
6.4.1	Low-density Lipoproteins as Carriers of Amphiphilic Gd(III) Complexes	197
6.4.2	Blood-Pool Agents for DCE-MRI Applications	198
6.5	Conclusions	200
	Acknowledgements	200
	References	201

<b>Chapter 7</b>	<b>Pharmacological fMRI in Drug Discovery and Development</b>	<b>204</b>
	<i>Alexandre Coimbra, Richard Baumgartner and Adam J. Schwarz</i>	
7.1	Introduction	204
7.2	Physiology of fMRI	205
7.3	fMRI Techniques	206
7.3.1	BOLD Imaging	206
7.3.2	CBF Imaging with Arterial Spin Labeling	207
7.3.3	CBV Imaging with Exogenous Contrast	207
7.4	fMRI Applications in Drug Research: Principles and Examples	208
7.4.1	Pre-Clinical Drug Discovery	208
7.4.2	Clinical Drug Development	211
7.4.3	Translation	214
7.5	Good Imaging Practice (GIP) for fMRI in Drug Studies	216
7.6	Analytical Tools for Functional Magnetic Resonance Imaging (fMRI) in Pharmacological Experiments	217
7.6.1	Primary Data Analysis Components	218
7.6.2	Task-Based fMRI and phMRI Experiments	219
7.6.3	Resting State Connectivity	220
7.6.4	Measures of Basal Hemodynamics	222
7.7	Challenges	222
	References	224
<b>Chapter 8</b>	<b><i>In Vivo</i> Proton MR Spectroscopy: Animal and Human Applications at High Fields</b>	<b>230</b>
	<i>Ivan Tkáč and Gülin Öz</i>	
8.1	Introduction	230
8.2	Methodology of Proton MRS at High Fields	231
8.2.1	Potentials for Neurochemical Profiling	231
8.2.2	Data Acquisition	232
8.2.3	Data Processing	235
8.2.4	Metabolite Quantification	236
8.3	Applications of Proton MRS at High Fields	238
8.3.1	Neurochemical Profiling in the Animal Brain	238
8.3.2	Neurochemical Profiling in the Human Brain	244
8.4	Conclusions	248
	References	249

<b>Chapter 9</b>	<b>Hyperpolarization: Concepts, Techniques and Applications</b>	<b>252</b>
	<i>Arnaud Comment</i>	
9.1	What is Hyperpolarization and Why Bother Using It?	252
9.1.1	Thermodynamic Considerations	255
9.1.2	The Principles of Hyperpolarization and Dynamic Nuclear Polarization Methods	256
9.1.3	The Importance of Spin Relaxation	258
9.1.4	Other Limitations	261
9.2	How to Hyperpolarize Nuclear Spins?	262
9.2.1	Brute Force Method	262
9.2.2	Dissolution Dynamic Nuclear Polarization	262
9.2.3	Parahydrogen-Induced Polarization	263
9.3	Applications of Hyperpolarized Magnetic Resonance in Drug Research	264
9.3.1	<i>In Vitro</i> Applications	265
9.3.2	<i>In Vivo</i> Applications	266
9.3.3	Perspectives for Clinical Applications	268
9.4	Conclusions	268
	Acknowledgements	269
	References	269
<b>Chapter 10</b>	<b>Combined PET/MRI for Improving Quantitative Imaging</b>	<b>273</b>
	<i>Tim D. Fryer</i>	
10.1	Introduction	273
10.2	Combined PET/MRI Designs	274
10.3	PET/MR Registration	276
10.4	Attenuation Correction	276
10.5	Motion Correction	278
10.6	Anatomically Guided Image Reconstruction	281
10.7	Anatomically Driven Post-Reconstruction Resolution Recovery and Denoising	281
10.8	Image-Based Input Function Estimation	283
10.9	Combined Functional Imaging	284
10.10	Clinical/Pre-Clinical Applications	285
10.11	Conclusion	285
	Acknowledgements	286
	References	286
<b>Chapter 11</b>	<b>Magnetic Resonance-Based Cell Imaging Using Contrast Media and Reporter Genes</b>	<b>293</b>
	<i>Greetje Vande Velde and Uwe Himmelreich</i>	
11.1	Introduction	293

11.2	Magnetic Resonance Techniques	294
11.2.1	Contrast Generation in MRI	295
11.2.2	Contrast Generation in MR Spectroscopic Imaging	298
11.3	MRI Contrast for Cellular and Molecular Imaging	299
11.3.1	Labeling Cells with Contrast Agents for MRI	299
11.3.2	MRI Contrast Agents Targeting Specific Cell Types	302
11.3.3	Contrast Agents Responsive to Chemical Modification	304
11.3.4	Genetic Reporter Systems	310
11.3.5	Direct Monitoring of Metabolic Pathways	318
11.4	Limitations and Perspectives	319
	Acknowledgements	320
	References	320

### **Part III Translational Drug Discovery: From Biological Models to the Clinics**

#### **Chapter 12 Translational Magnetic Resonance Imaging and Spectroscopy: Opportunities and Challenges 333**

*John C. Waterton*

12.1	Translational Magnetic Resonance Imaging and Spectroscopy	333
12.2	NMR Measurements as Biomarkers	336
12.2.1	Biomarker Definition	336
12.2.2	Biomarker Qualification	338
12.2.3	Technical Validity	346
12.2.4	Biological Validity	350
12.3	MR Biomarkers in Practice	353
12.4	Unmet Needs and Opportunities	353
	References	354

#### **Chapter 13 In Vivo MRI/S for the Safety Evaluation of Pharmaceuticals 361**

*Paul D. Hockings and Helen Powell*

13.1	Introduction	361
13.2	Hepatotoxicity	364
13.2.1	Hepatic Steatosis	365
13.2.2	Hepatobiliary Transporter Inhibition	367
13.3	Cardiotoxicity	369
13.4	Conclusion	371
	References	373

<b>Chapter 14 Applications of MRI and MRS in Cartilage Therapeutics and Tissue Engineering</b>	<b>376</b>
<i>David A. Reiter and Richard G. Spencer</i>	
14.1 Introduction	376
14.2 Hollow Fiber Bioreactor Studies	377
14.2.1 $^1\text{H}$ MRI Studies of Hollow Fiber Bioreactor Cartilage	380
14.2.2 Hollow Fiber Bioreactor Studies Using Complementary Spectroscopic and Imaging Techniques	380
14.3 Modulation of Neocartilage Growth	386
14.3.1 Nutrients, Anabolic Agents and Growth Factors	386
14.3.2 Mechanical Stimulation	387
14.3.3 Catabolic Agents	389
14.4 Translational Studies: Tissue Integration and Assessment Using MRI	389
14.5 Sensitivity and Specificity Improvements in Proton MRI	392
14.5.1 Alternative Models of Transverse Relaxation	392
14.5.2 Multivariate Machine Learning Analysis of MRI Parameters	394
14.5.3 Combined Multivariate and Multiexponential Analysis	398
14.6 Conclusions	398
Acknowledgement	398
References	399
<b>Chapter 15 Applications of Magnetic Resonance Spectroscopy to Psychiatric Disorders</b>	<b>405</b>
<i>Richard A. Komoroski</i>	
15.1 Introduction	405
15.1.1 Scope	405
15.1.2 <i>In Vivo</i> MRS in the Study of Psychiatric Disorders	406
15.1.3 Animal Models and <i>Ex Vivo</i> Studies	407
15.2 Information Content of <i>In Vivo</i> MRS of Brain	408
15.2.1 $^1\text{H}$ MRS	408
15.2.2 $^{31}\text{P}$ MRS	410
15.2.3 $^{13}\text{C}$ MRS	411
15.2.4 Direct Detection of Psychoactive Drugs by $^{19}\text{F}$ and $^7\text{Li}$ MRS	412

15.3	Applications to Specific Disorders	414
15.3.1	Schizophrenia	414
15.3.2	Bipolar Disorder (BPD)	415
15.3.3	Major Depressive Disorder (MDD)	416
15.3.4	Other Psychiatric Disorders	416
15.4	Future Directions	417
15.4.1	Technically Oriented Directions	417
15.4.2	Clinically Oriented Directions	417
	Acknowledgements	418
	References	418

**Chapter 16 Structural Magnetic Resonance Imaging Biomarkers in Neurodegenerative Disease** **422**  
*Linda K. McEvoy, Dominic Holland and Anders M. Dale*

16.1	Introduction	422
16.2	Technical Considerations	423
16.2.1	Standardized Data Acquisition Protocols	423
16.2.2	Artifact Minimization	424
16.2.3	Automated Image Segmentation and Quantification	427
16.2.4	Longitudinal Image Analysis	428
16.3	Clinical Trial Design	429
16.3.1	MRI for Clinical Trial Enrichment	430
16.3.2	MRI as an Outcome Variable	431
16.4	Caveats and Conclusions	433
	References	434

**Chapter 17 Magnetic Resonance Imaging in Respiratory Diseases: From Diagnosis to Pharmaceutical Research and Development** **441**  
*Nicolau Beckmann, Alexandre Trifilieff, Christine Egger and Yannick Cr  millieux*

17.1	Introduction	441
17.2	Lung Imaging: Basic Considerations	442
17.3	MRI in Respiratory Diseases: From Animal Models to Patients	444
17.3.1	Airway Inflammation	445
17.3.2	Mucus Secretion and Clearance	447
17.3.3	Emphysema	449
17.3.4	Lung Ventilation and Perfusion	453
17.3.5	Lung Fibrosis	457
17.3.6	Infections	459
17.3.7	Pulmonary Arterial Hypertension	461



17.3.8	Side Effects from Inhaled Pollutants or Particles	462
17.4	Final Remarks	464
	References	465
<b>Chapter 18</b>	<b>Cardiovascular Magnetic Resonance</b>	<b>472</b>
	<i>Alex Pitcher, Theodoros D. Karamitsos, Jürgen E. Schneider and Stefan Neubauer</i>	
18.1	Scope of the Problem: the Global Burden of Cardiovascular Disease	472
18.2	Definition of CMR and an Overview of the Clinical Role of CMR	472
18.3	Overview of the Current Status of CMR (Imaging and Spectroscopy) and the Rationale for the Use of CMR in Drug Evaluation	473
18.4	CMR in Pre-Clinical Drug Development	475
18.5	CMR in Clinical Drug Development: Current Status of CMR for Interrogating Aspects of Cardiovascular Tissue and Function	476
18.5.1	Vascular Imaging	476
18.5.2	Ischemic Heart Disease	478
18.5.3	Cardiomyopathy	480
18.6	Limitations of CMR	482
18.7	Future Perspectives: Emerging CMR Techniques Likely to Aid Evaluation of Emerging Therapies (Pre-Clinical and Clinical Sections)	483
	Acknowledgements	484
	References	484
<b>Chapter 19</b>	<b>Magnetic Resonance Imaging Techniques in Cancer</b>	<b>490</b>
	<i>D. M. Morris, J. P. B. O'Connor and A. Jackson</i>	
19.1	Overview	490
19.2	Relaxation Times and Proton Density	491
19.2.1	Clinical Use of "Weighted" Sequences	492
19.2.2	Quantifying $T_1$ and $T_2^*$	494
19.3	Dynamic Contrast Enhanced MRI (DCE-MRI)	495
19.3.1	Dynamic Susceptibility Contrast Enhanced-MRI (DSCE-MRI)	495
19.3.2	Dynamic Relaxivity Contrast Enhanced MRI (DRCE-MRI)	498
19.4	Diffusion Weighted Imaging	501
19.4.1	Apparent Diffusion Coefficient	501
19.4.2	Clinical Applications	502